Ulrich T Hacker
Overview
Explore the profile of Ulrich T Hacker including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
396
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Araujo A, Bentler M, Perez Garmendia X, Kaleem A, Fabian C, Morgan M, et al.
Hum Gene Ther
. 2024 Aug;
35(17-18):586-603.
PMID: 39193633
All current market-approved gene therapy medical products for gene therapy of monogenic diseases rely on adeno-associated virus (AAV) vectors. Advances in gene editing technologies and vector engineering have expanded the...
2.
Kerle I, Scheuble A, Kobitzsch B, Stocker G, Hiller G, Badendick M, et al.
JCO Precis Oncol
. 2024 May;
8:e2400030.
PMID: 38820503
Complete remission of BRAF V600E-driven ACC CUP by BRAF/MEK inhibition underscores importance of precision oncology.
3.
Alberti A, Stocker G, Lordick F, Hacker U, Kobitzsch B, Haffner I, et al.
Front Oncol
. 2023 Nov;
13:1276138.
PMID: 37941551
Purpose: The Cancer Genome Atlas Research Network identified Epstein-Barr-Virus (EBV)-positive gastric cancer as a distinct molecular subtype. The prevalence is 8-9% and the histological examination shows pronounced lymphocytic infiltration, elevated...
4.
Pouyiourou M, Kraft B, Wohlfromm T, Stahl M, Kubuschok B, Loffler H, et al.
Nat Commun
. 2023 Oct;
14(1):6761.
PMID: 37875494
Cancer of unknown primary has a dismal prognosis, especially following failure of platinum-based chemotherapy. 10-20% of patients have a high tumor mutational burden (TMB), which predicts response to immunotherapy in...
5.
Boeschen M, Kuhn C, Wirtz H, Seyfarth H, Frille A, Lordick F, et al.
Lung Cancer
. 2023 Sep;
184:107361.
PMID: 37699269
Objectives: Mutations in STK11 (STK11) and KEAP1 (KEAP1) occur frequently in non-small cell lung cancer (NSCLC) and are often co-mutated with KRAS. Several studies linked the co-occurrence of KRAS + ...
6.
Bentler M, Hardet R, Ertelt M, Rudolf D, Kaniowska D, Schneider A, et al.
Mol Ther Methods Clin Dev
. 2023 Sep;
30:576-592.
PMID: 37693943
immune responses are considered major challenges in gene therapy. With the aim to lower innate immune responses directly in cells targeted by adeno-associated virus (AAV) vectors, we equipped the vector...
7.
8.
Meumann N, Schmithals C, Elenschneider L, Hansen T, Balakrishnan A, Hu Q, et al.
Cancers (Basel)
. 2022 Jan;
14(2).
PMID: 35053588
Although therapeutic options are gradually improving, the overall prognosis for patients with hepatocellular carcinoma (HCC) is still poor. Gene therapy-based strategies are developed to complement the therapeutic armamentarium, both in...
9.
Westphalen C, Bokemeyer C, Buttner R, Frohling S, Gaidzik V, Glimm H, et al.
Eur J Cancer
. 2021 Dec;
162:245-246.
PMID: 34953660
No abstract available.
10.
Korfer J, Lordick F, Hacker U
Cancers (Basel)
. 2021 Oct;
13(20).
PMID: 34680363
Gastric cancer is a leading cause of cancer death worldwide. Systemic treatment comprising chemotherapy and targeted therapy is the standard of care in advanced/metastatic gastric cancer. Comprehensive molecular characterization of...